JP2016522235A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016522235A5 JP2016522235A5 JP2016520456A JP2016520456A JP2016522235A5 JP 2016522235 A5 JP2016522235 A5 JP 2016522235A5 JP 2016520456 A JP2016520456 A JP 2016520456A JP 2016520456 A JP2016520456 A JP 2016520456A JP 2016522235 A5 JP2016522235 A5 JP 2016522235A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- syndrome
- formula
- agent according
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003795 chemical substances by application Substances 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 13
- 208000023105 Huntington disease Diseases 0.000 claims 10
- 208000000323 Tourette Syndrome Diseases 0.000 claims 9
- 208000016620 Tourette disease Diseases 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 208000035475 disorder Diseases 0.000 claims 8
- 239000002552 dosage form Substances 0.000 claims 8
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 7
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 7
- 229940124597 therapeutic agent Drugs 0.000 claims 7
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims 6
- 208000005793 Restless legs syndrome Diseases 0.000 claims 6
- 208000018839 Wilson disease Diseases 0.000 claims 6
- 208000013403 hyperactivity Diseases 0.000 claims 6
- 206010008748 Chorea Diseases 0.000 claims 5
- 208000012661 Dyskinesia Diseases 0.000 claims 5
- 206010043118 Tardive Dyskinesia Diseases 0.000 claims 5
- 208000012601 choreatic disease Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 206010003591 Ataxia Diseases 0.000 claims 2
- 206010010904 Convulsion Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 208000010118 dystonia Diseases 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 238000011282 treatment Methods 0.000 claims 2
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 claims 1
- DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 claims 1
- 229940100578 Acetylcholinesterase inhibitor Drugs 0.000 claims 1
- 208000009017 Athetosis Diseases 0.000 claims 1
- 206010058504 Ballismus Diseases 0.000 claims 1
- 208000002033 Myoclonus Diseases 0.000 claims 1
- LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 claims 1
- QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 claims 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 claims 1
- 206010044565 Tremor Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 239000000544 cholinesterase inhibitor Substances 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 238000011284 combination treatment Methods 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 229960003530 donepezil Drugs 0.000 claims 1
- 229960003638 dopamine Drugs 0.000 claims 1
- 230000001815 facial effect Effects 0.000 claims 1
- 230000035873 hypermotility Effects 0.000 claims 1
- 230000001622 hypnogenic effect Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 239000003176 neuroleptic agent Substances 0.000 claims 1
- BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 claims 1
- 229960003147 reserpine Drugs 0.000 claims 1
- 229960004181 riluzole Drugs 0.000 claims 1
- MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 claims 1
- 229960005333 tetrabenazine Drugs 0.000 claims 1
- 210000003371 toe Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13382230 | 2013-06-19 | ||
| EP13382230.4 | 2013-06-19 | ||
| PCT/EP2014/062786 WO2014202646A1 (en) | 2013-06-19 | 2014-06-18 | Therapeutic agents for use in the prophylaxis and/or treatment of hyperkinetic movement disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016522235A JP2016522235A (ja) | 2016-07-28 |
| JP2016522235A5 true JP2016522235A5 (enExample) | 2017-07-20 |
| JP6476174B2 JP6476174B2 (ja) | 2019-02-27 |
Family
ID=48672545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016520456A Active JP6476174B2 (ja) | 2013-06-19 | 2014-06-18 | 運動過剰障害の予防および／または治療における使用のための治療剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US9789072B2 (enExample) |
| EP (1) | EP3010543B1 (enExample) |
| JP (1) | JP6476174B2 (enExample) |
| KR (1) | KR102254542B1 (enExample) |
| CN (1) | CN105658238B (enExample) |
| AU (1) | AU2014283319B2 (enExample) |
| BR (1) | BR112015031835B1 (enExample) |
| CA (1) | CA2915811C (enExample) |
| CL (1) | CL2015003679A1 (enExample) |
| DK (1) | DK3010543T3 (enExample) |
| HK (1) | HK1223014A1 (enExample) |
| IL (1) | IL243192B (enExample) |
| MX (1) | MX366353B (enExample) |
| PT (1) | PT3010543T (enExample) |
| RU (1) | RU2685502C2 (enExample) |
| SG (1) | SG11201510451RA (enExample) |
| WO (1) | WO2014202646A1 (enExample) |
| ZA (1) | ZA201600312B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41557A (fr) * | 2015-02-18 | 2017-12-26 | Auspex Pharmaceuticals Inc | Inhibiteurs diméthoxyphényles du transporteur vésiculaire des monoamines 2 |
| EP3684333B1 (en) * | 2017-09-21 | 2025-03-05 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| MY198713A (en) | 2017-10-10 | 2023-09-19 | Neurocrine Biosciences Inc | Methods for the administration of certain vmat2 inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE790165A (fr) * | 1971-12-14 | 1973-02-15 | Parke Davis & Co | Nouveaux aminoalcanols et procede pour les preparer |
| US20090137837A1 (en) * | 2007-06-21 | 2009-05-28 | Amgen Inc. | Methods of synthesizing cinacalcet and salts thereof |
| CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| US8197858B2 (en) * | 2009-02-06 | 2012-06-12 | Mark John Zamoyski | Bone microenvironment modulated seizure treatments |
| UA115968C2 (uk) | 2011-03-01 | 2018-01-25 | Фарнекст | Нові композиції для лікування неврологічних захворювань |
| EP2705842A1 (en) | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| ES2450074T3 (es) * | 2011-03-01 | 2014-03-21 | Pharnext | Terapia para trastornos neurológicos basada en baclofeno y acamprosato |
-
2014
- 2014-06-18 KR KR1020167001456A patent/KR102254542B1/ko active Active
- 2014-06-18 CA CA2915811A patent/CA2915811C/en active Active
- 2014-06-18 WO PCT/EP2014/062786 patent/WO2014202646A1/en not_active Ceased
- 2014-06-18 US US14/900,028 patent/US9789072B2/en active Active
- 2014-06-18 DK DK14731261.5T patent/DK3010543T3/da active
- 2014-06-18 PT PT147312615T patent/PT3010543T/pt unknown
- 2014-06-18 RU RU2016101152A patent/RU2685502C2/ru active
- 2014-06-18 SG SG11201510451RA patent/SG11201510451RA/en unknown
- 2014-06-18 MX MX2015018040A patent/MX366353B/es active IP Right Grant
- 2014-06-18 EP EP14731261.5A patent/EP3010543B1/en active Active
- 2014-06-18 AU AU2014283319A patent/AU2014283319B2/en active Active
- 2014-06-18 HK HK16111181.8A patent/HK1223014A1/zh unknown
- 2014-06-18 CN CN201480040973.6A patent/CN105658238B/zh active Active
- 2014-06-18 BR BR112015031835-5A patent/BR112015031835B1/pt active IP Right Grant
- 2014-06-18 JP JP2016520456A patent/JP6476174B2/ja active Active
-
2015
- 2015-12-17 IL IL243192A patent/IL243192B/en active IP Right Grant
- 2015-12-18 CL CL2015003679A patent/CL2015003679A1/es unknown
-
2016
- 2016-01-14 ZA ZA2016/00312A patent/ZA201600312B/en unknown
-
2017
- 2017-09-22 US US15/713,372 patent/US20180042869A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016534063A5 (enExample) | ||
| PH12018500212A1 (en) | 1,3,4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | |
| JP2018021051A5 (enExample) | ||
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2015537020A5 (enExample) | ||
| RU2013121788A (ru) | Ингибиторы репликации вич | |
| JP2012255026A5 (enExample) | ||
| JP2013534248A5 (enExample) | ||
| JP2014515373A5 (enExample) | ||
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| JP2016522254A5 (enExample) | ||
| PH12015501945B1 (en) | Formulations of organic compounds | |
| JP2014530818A5 (enExample) | ||
| JP2015516419A5 (enExample) | ||
| JP2016515550A5 (enExample) | ||
| JP2016531846A5 (enExample) | ||
| JP2016530242A5 (enExample) | ||
| PH12014500191A1 (en) | Use of organic compound for the treatment of noonan syndrome | |
| JP2016522235A5 (enExample) | ||
| JP2014530204A5 (enExample) | ||
| JP2014148552A5 (enExample) | ||
| RU2014128387A (ru) | Ингибиторы рi3к для лечения фиброзных заболеваний | |
| JP2014509637A5 (enExample) | ||
| JP2019516726A5 (enExample) | ||
| PH12019502510A1 (en) | Pharmaceutical composition and pharmaceutical dosage form comprising (e)-4-(2-(aminomethyl)-3-fluoroallyloxy)-n-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof |